The Science Behind Polygenic Risk Scores - Explained Simply

A few years ago, polygenic risk scores were a research concept. Now they appear in clinical settings, insurance actuarial models, and direct-to-consumer reports. Most people receiving them have no idea what the number actually means. That's not a small problem.

This piece isn't going to make you a population geneticist, but it should give you enough to understand what you're looking at when a report tells you you're in the "high" or "elevated" category for a particular condition.

Single variants versus polygenic scores

Some genetic effects are monogenic, meaning one variant causes a predictable outcome. Huntington's disease works this way. If you carry the CAG repeat expansion in the HTT gene above a certain threshold, you will develop the disease if you live long enough. That's deterministic.

Most common conditions don't work like that. Type 2 diabetes, coronary artery disease, schizophrenia, and hundreds of other conditions are influenced by thousands of variants, each contributing a tiny amount to overall risk. No single variant is decisive. The disease emerges from the combined effect of many small pushes in one direction.

A polygenic risk score adds up those small effects. Researchers identify variants associated with a condition through genome-wide association studies, assign each a weight based on how much it increases or decreases risk, and then calculate a total score for an individual by summing the weighted effects across all included variants.

How the studies behind the score are built

A genome-wide association study, or GWAS, works by comparing genetic data from large groups of people who have a given condition with people who don't. Researchers look for variants that appear more frequently in the affected group. The signal for any individual variant is usually tiny - an odds ratio of 1.05 or 1.08, meaning a 5 to 8 percent increase in relative risk. But when you combine hundreds or thousands of these across the genome, the aggregate score can meaningfully stratify risk.

The quality of the score depends heavily on the size and diversity of the discovery cohort. Early GWAS were conducted almost exclusively in European-ancestry populations. Scores built on those studies perform worse in people of African, East Asian, South Asian, or Latin American ancestry. This is a genuine scientific limitation, not a technicality. GeneLens uses ancestry-adjusted scoring where population-specific validation data exists, and we are explicit in our reports about which scores have limited validation in your ancestry group.

What the score means for you

A polygenic risk score places you somewhere on a distribution - typically expressed as a percentile or a relative risk multiplier compared to the average. Being in the 90th percentile for coronary artery disease means your genetic risk is higher than 90% of the reference population. It does not mean you have a 90% chance of having a heart attack.

This distinction matters. Absolute risk and relative risk tell different stories. If the baseline population lifetime risk for a condition is 5%, being at 2x polygenic risk puts your genetic contribution at roughly 10%. That's elevated, but it's not a certainty, and it's modifiable by behavior and clinical management.

The most useful application of a high PRS is to trigger earlier screening or more intensive preventive care. Someone with a high polygenic score for colorectal cancer might begin colonoscopies earlier than standard guidelines recommend. Someone with elevated cardiovascular PRS might prioritize statin use and more frequent lipid monitoring. The score informs action, not fate.

Where the science still has gaps

Polygenic scores explain only a portion of heritability for most conditions. Even the best-validated scores for coronary artery disease explain around 20-30% of genetic risk. The rest comes from rare variants not captured in GWAS, gene-environment interactions, and effects researchers haven't characterized yet.

There's also the question of how scores translate across the lifespan. Most discovery cohorts are adults. Whether a PRS calculated in middle age accurately represents risk trajectories for younger people is an active research question.

Clinical implementation is another frontier. Guidelines from bodies like the American Heart Association are beginning to incorporate PRS into risk calculators, but the field is moving faster than the guidelines. Your clinician may not yet have a clear protocol for what to do with your score.

How to use yours

The right response to a high polygenic risk score is a conversation with your doctor, not a spiral. Bring the report. Ask specifically what preventive measures or screening protocols make sense given your score, your family history, and your other risk factors. The genetics are one input into a broader clinical picture.

A low score doesn't mean you're protected. Cardiovascular disease kills people with low polygenic risk all the time, because lifestyle factors matter enormously. Genetics gives you part of the picture. It's a useful part. But it's not the whole picture, and any test that implies otherwise is misrepresenting what the science can do.